Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358813 · ClinicalTrials.gov registry record · Phase 1
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00358813 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 18 participants.
The verdict
NCT00358813, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate how subjects with mild or moderate kidney problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
Interventions
- DRUG Casopitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-09-08 |
| Est. Completion | 2008-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358813
The ClinicalTrials.gov registry entry for NCT00358813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Casopitant is the first listed.
NCT00358813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358813 about?
NCT00358813 is a clinical study titled "Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment". The purpose of the study is to evaluate how subjects with mild or moderate kidney problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
What is the current status of trial NCT00358813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-09-08. Estimated completion is 2008-08-22.
What interventions are being tested in trial NCT00358813?
The interventions under investigation include: Casopitant (DRUG).
Who is sponsoring clinical trial NCT00358813?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.